Please login to the form below

Not currently logged in
Email:
Password:

GSK's Cervarix HPV vaccine approved in Kenya

GlaxoSmithKline's HPV vaccine Cervarix is now available in Kenya after the country's Pharmacy and Poison's Board approved it for marketing

GlaxoSmithKline's (GSK) human papillomavirus (HPV) vaccine Cervarix has become available in Kenya after the country's Pharmacy and Poison's Board approved it for marketing.

Cervarix has been shown to be 100 per cent effective in preventing infection with HPV strains 16 and 18, which together cause about 70 per cent of cervical cancer cases.

Kenya is now the third country after Australia and the United Arab Emirates to approve marketing of Cervarix after the pharmacy board approved GSK's application in June 2007.

GSK has not yet revealed the price of the vaccine in the country, but it may cost in the region of USD 300, according to local media reports. Other reports say that Kenyans will be unable to afford the vaccine and that the government would lobby health donors to buy bulk quantities of Cervarix. The Kenyan government does not have the authority to issue price controls for the vaccine.

Director of medical and regulatory affairs in East Africa for GSK, William Mwatu, said that the company was continuing to assess the cost and supply details of Cervarix in Kenya.

3rd September 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics